Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company is projected to generate revenue of 2.649 billion RMB in 2025, representing a decline of 5.8% year-over-year, with adjusted net profit expected to be 209 million RMB, down 49.7% year-over-year. The decline is attributed to an increase in the proportion of artificial insemination (IUI) affecting the number of egg retrieval cycles and pricing, along with zero markup on drug costs. However, there is a significant improvement expected in the second half of the year [1][5] - For 2026, the outlook is positive, driven by the implementation of the California commercial insurance law SB729, which is expected to catalyze a 38% year-over-year increase in cycle numbers in January and February. The new facility in Shenzhen is also expected to contribute positively, with a projected 18% year-over-year increase in cycle numbers [1][2] Summary by Sections Domestic Business - The revenue in the Greater Bay Area is expected to decline by 8.8% to 420 million RMB in 2025, primarily due to a higher proportion of lower-cost IUI cycles and delays in the relocation of the Shenzhen facility. However, a double-digit year-over-year growth is anticipated for the Shenzhen region in 2026, supported by a significant increase in capacity and higher customer pricing through premium services [2][3] Overseas Business - The HRC Fertility business in the U.S. is expected to benefit from the acceleration of commercial insurance coverage, with a projected revenue increase of 5.1% year-over-year in 2025. The implementation of SB729 is expected to enhance cycle numbers significantly, with a 38% year-over-year increase in January and February [3][4] Financial Forecast and Valuation - The company is expected to achieve adjusted EPS of 0.11 RMB in 2026, with a target price set at 3.25 HKD, reflecting a 26x PE ratio. This valuation considers the potential positive impact of the U.S. insurance coverage on revenue and pricing strategies [5][11]
锦欣生殖:深圳新院贡献新动能,海外或受益商保-20260330
HTSC·2026-03-30 10:50